Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
Ticker SymbolVXRT
Company nameVaxart Inc
IPO dateMar 17, 1980
CEOMr. Steven (Steve) Lo
Number of employees105
Security typeOrdinary Share
Fiscal year-endMar 17
Address170 Harbor Way, Suite 300
CitySOUTH SAN FRANCISCO
Stock exchangeUS 'Other OTC' and Grey Market
CountryUnited States of America
Postal code94080
Phone16505503500
Websitehttps://vaxart.com/
Ticker SymbolVXRT
IPO dateMar 17, 1980
CEOMr. Steven (Steve) Lo
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data